PR Diabetes y Endocrinología icon

v3.1.1 by Clyna S.A.


Feb 23, 2023

About PR Diabetes y Endocrinología

Information on drugs marketed in Argentina.

PR Vademecum contains updated information on medicines and prescription drugs marketed in Argentina.

To activate the application it is necessary to have the username and code provided by Lazar.

The application allows access by the following indexes:

- Products

Contains the text of the prospectus of the products that are marketed in Argentina.

- Laboratories

It contains the list of laboratories and the products that each one sells.

- Pathologies

Contains the list of pathologies and the products indicated for each one

- Interactions

It contains the list of active principles and the interactions of each one.

- Pharmacological Index

Contains the text of the action of the active ingredients.

- Therapeutic Index

It contains the list of therapeutic actions and the products indicated for each one.

- I.S.P.R. Index of Substances and Related Products

It contains a list of the principles and the products that each one contains.

P.R. VADEMÉCUM was developed from reliable sources, such as manufacturing companies and the medical-pharmacological bibliography available today.

For inquiries send email to: [email protected]

What's New in the Latest Version v3.1.1

Last updated on Nov 24, 2015

Actualización de contenido.

Translation Loading...

Additional APP Information

Latest Version

Request PR Diabetes y Endocrinología Update v3.1.1

Uploaded by

Milan Rai

Requires Android

Android 2.1+

Available on

Get PR Diabetes y Endocrinología on Google Play

Show More

PR Diabetes y Endocrinología Screenshots

Comment Loading...
Languages
Searching...
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.